RU 486 BEING TESTED AS POSTCOITAL CONTRACEPTIVE
RU 486 BEING TESTED AS POSTCOITAL CONTRACEPTIVE in a trial that will enroll 150 women in the San Francisco Bay Area, the University of California-San Francisco announced May 3. Under an IND approved by FDA, the women will receive the antiprogestin mifepristone as an emergency "morning-after pill." The study is part of a larger 2,100-patient trial being sponsored by the World Health Organization at 14 sites worldwide.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth